Reshma Kewalramani is the President and Chief Executive Officer of Vertex Pharmaceuticals Incorporated, a global biotechnology company that focuses on developing transformative medicines for serious diseases. Dr. Kewalramani joined Vertex in 2017 as the Chief Medical Officer and Executive Vice President, and assumed her current role as CEO in April 2020. She holds an M.D. from the Boston University School of Medicine and an M.B.A. from the Wharton School of the University of Pennsylvania. Prior to joining Vertex, she completed her internal medicine residency and nephrology fellowship at Massachusetts General Hospital and served as a faculty member at Harvard Medical School and Massachusetts General Hospital. Under Dr. Kewalramani's leadership, Vertex has continued to advance its mission of creating innovative treatments for patients with serious diseases, particularly cystic fibrosis (CF). During her tenure, the company has successfully launched several new CF medicines, including Trikafta, which has significantly improved the lives of many CF patients. In addition to her work in CF, Dr. Kewalramani has overseen the expansion of Vertex's research and development pipeline into other disease areas, such as sickle cell disease, beta thalassemia, and pain. Her strategic vision and commitment to scientific excellence have positioned Vertex as a leader in the biotechnology industry. As CEO, Dr. Kewalramani plays a crucial role in guiding Vertex's overall strategy and operations. She is responsible for overseeing the company's global business, including its research and development, manufacturing, and commercial activities. Dr. Kewalramani is also a strong advocate for diversity and inclusion in the workplace, and she has implemented initiatives to promote a culture of equity and belonging at Vertex. Her leadership has been recognized by various organizations, including her inclusion in Fortune's Most Powerful Women in Business list and Forbes' 50 Over 50 list.